DFTX · Definium Therapeutics Inc
United States · RS rating 61 · As of 2026-10-14
| Price | 34.24 USD |
|---|---|
| 1-day change | -0.4% |
| RS rating (overall / 1M / 3M / 12M) | 61 / 30 / 17 / 97 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 37 / 50 / 21 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -102.8% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +29.3% |
| Market cap (USD) | $2.3B |